Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 66

1.

Primuline derivatives that mimic RNA to stimulate hepatitis C virus NS3 helicase-catalyzed ATP hydrolysis.

Sweeney NL, Shadrick WR, Mukherjee S, Li K, Frankowski KJ, Schoenen FJ, Frick DN.

J Biol Chem. 2013 Jul 5;288(27):19949-57. doi: 10.1074/jbc.M113.463166. Epub 2013 May 23.

2.

Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation.

Ndjomou J, Kolli R, Mukherjee S, Shadrick WR, Hanson AM, Sweeney NL, Bartczak D, Li K, Frankowski KJ, Schoenen FJ, Frick DN.

Antiviral Res. 2012 Nov;96(2):245-55. doi: 10.1016/j.antiviral.2012.08.006. Epub 2012 Aug 25.

3.

Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays.

Mukherjee S, Hanson AM, Shadrick WR, Ndjomou J, Sweeney NL, Hernandez JJ, Bartczak D, Li K, Frankowski KJ, Heck JA, Arnold LA, Schoenen FJ, Frick DN.

Nucleic Acids Res. 2012 Sep 1;40(17):8607-21. Epub 2012 Jun 27.

4.

Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline.

Li K, Frankowski KJ, Belon CA, Neuenswander B, Ndjomou J, Hanson AM, Shanahan MA, Schoenen FJ, Blagg BS, Aubé J, Frick DN.

J Med Chem. 2012 Apr 12;55(7):3319-30. doi: 10.1021/jm300021v. Epub 2012 Mar 22.

5.

Fluoroquinolones inhibit HCV by targeting its helicase.

Khan IA, Siddiqui S, Rehmani S, Kazmi SU, Ali SH.

Antivir Ther. 2012;17(3):467-76. doi: 10.3851/IMP1937. Epub 2011 Oct 25. Erratum in: Antivir Ther. 2012;17(3):595.

PMID:
22293206
6.

Hepatitis C: move over interferon.

Garber K.

Nat Biotechnol. 2011 Nov 8;29(11):963-6. doi: 10.1038/nbt.2031. No abstract available.

PMID:
22068526
7.

Telaprevir for retreatment of HCV infection.

Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team.

N Engl J Med. 2011 Jun 23;364(25):2417-28. doi: 10.1056/NEJMoa1013086.

8.

Boceprevir for previously treated chronic HCV genotype 1 infection.

Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1207-17. doi: 10.1056/NEJMoa1009482.

9.

Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase.

Mousseau G, Kota S, Takahashi V, Frick DN, Strosberg AD.

J Gen Virol. 2011 Jan;92(Pt 1):101-11. doi: 10.1099/vir.0.023325-0. Epub 2010 Sep 29.

10.

Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase.

Gemma S, Butini S, Campiani G, Brindisi M, Zanoli S, Romano MP, Tripaldi P, Savini L, Fiorini I, Borrelli G, Novellino E, Maga G.

Bioorg Med Chem Lett. 2011 May 1;21(9):2776-9. doi: 10.1016/j.bmcl.2010.09.002. Epub 2010 Sep 6.

PMID:
20880703
11.

Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication.

Najda-Bernatowicz A, Krawczyk M, Stankiewicz-Drogoń A, Bretner M, Boguszewska-Chachulska AM.

Bioorg Med Chem. 2010 Jul 15;18(14):5129-36. doi: 10.1016/j.bmc.2010.05.066. Epub 2010 Jun 2.

PMID:
20579888
12.

Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication.

Stankiewicz-Drogoń A, Dörner B, Erker T, Boguszewska-Chachulska AM.

J Med Chem. 2010 Apr 22;53(8):3117-26. doi: 10.1021/jm901741p.

PMID:
20337460
13.

A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities.

Frick DN, Ginzburg O, Lam AM.

Methods Mol Biol. 2010;587:223-33. doi: 10.1007/978-1-60327-355-8_16.

14.
15.

Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor.

Belon CA, High YD, Lin TI, Pauwels F, Frick DN.

Biochemistry. 2010 Mar 9;49(9):1822-32. doi: 10.1021/bi901974a.

16.

Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism.

Gu M, Rice CM.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):521-8. doi: 10.1073/pnas.0913380107. Epub 2009 Dec 31.

17.

Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions.

Sharp A, Crabb SJ, Johnson PW, Hague A, Cutress R, Townsend PA, Ganesan A, Packham G.

J Pharmacol Exp Ther. 2009 Nov;331(2):680-9. doi: 10.1124/jpet.109.153601. Epub 2009 Aug 18.

18.

Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.

Chen CS, Chiou CT, Chen GS, Chen SC, Hu CY, Chi WK, Chu YD, Hwang LH, Chen PJ, Chen DS, Liaw SH, Chern JW.

J Med Chem. 2009 May 14;52(9):2716-23. doi: 10.1021/jm8011905.

PMID:
19419203
19.

Discovery of a novel HCV helicase inhibitor by a de novo drug design approach.

Kandil S, Biondaro S, Vlachakis D, Cummins AC, Coluccia A, Berry C, Leyssen P, Neyts J, Brancale A.

Bioorg Med Chem Lett. 2009 Jun 1;19(11):2935-7. doi: 10.1016/j.bmcl.2009.04.074. Epub 2009 Apr 22.

PMID:
19414257
20.

Fuel specificity of the hepatitis C virus NS3 helicase.

Belon CA, Frick DN.

J Mol Biol. 2009 May 15;388(4):851-64. doi: 10.1016/j.jmb.2009.03.059. Epub 2009 Mar 28.

Supplemental Content

Support Center